Eton Pharmaceuticals’ new drug application (NDA) for Khindivi, an oral solution of hydrocortisone, has received US Food and Drug Administration (FDA) approval as a replacement therapy for ...

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced the US Food and Drug Administration (FDA) approval of ...

KHINDIVI is the first and only FDA-approved hydrocortisone oral solution • Commercial launch expected the week of June 2 nd • Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE ...

. Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone) oral granules to exceed $50 million DEER PARK, Ill., May 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, I ...

It does not require refrigeration, mixing or shaking as it is a ready-to-use oral liquid solution. Khindivi will be promoted by Eton’s existing team of pediatric endocrinology rare disease ...

oral solution in people with narcolepsy. These results are two of Jazz's four late-breaking abstracts presented today as oral presentations at SLEEP 2025. The four late-breaking abstracts ...

Eton Pharmaceuticals has announced the FDA approval of KHINDIVI, the first and only hydrocortisone oral solution for pediatric patients aged five and older with adrenocortical insufficiency.

After use, packaging treated with the material can be readily composted or recycled—closing the loop on a truly sustainable solution. GO-Eco—a subsidiary of Chang Robotics and a resident ...

KHINDIVI is the only FDA-approved oral solution formulation of hydrocortisone. It comes in a 1mg/ml strength designed to eliminate the need to split or crush tablets, and to offer simple and ...